| Dec 29 2022 |
Petition Filed to Add Polyoxymethylene to List of Chemical Substances Subject to Superfund Excise Tax |
Bergeson & Campbell, P.C. |
| Dec 29 2022 |
Doctor-Patient Relationships and Medical Marijuana: Where Are We Now? |
McDermott Will & Schulte LLP |
| Dec 28 2022 |
EPA Finds Carbon Tetrachloride, as a Whole Chemical Substance, Poses an Unreasonable Risk to Human Health |
Bergeson & Campbell, P.C. |
| Dec 28 2022 |
Consolidated Appropriations Act, 2023 Contains Significant Provisions for Cosmetic Products |
ArentFox Schiff LLP |
| Dec 28 2022 |
RxDC Reporting Relief for Plans, Issuers, and Plan Service Providers |
Foley & Lardner LLP |
| Dec 28 2022 |
Federal Regulators Offer Employer Health Plans Last-Minute Relief on Prescription Drug Reporting |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Dec 27 2022 |
EPA Announces Removal of PFAS Chemicals from Approved Inert Ingredient List for Pesticide Products |
Bergeson & Campbell, P.C. |
| Dec 27 2022 |
FDA Expands Inspection Guidance to Apply to Device Manufacturers |
Sheppard, Mullin, Richter & Hampton LLP |
| Dec 24 2022 |
Back to the Drawing Board: CMS Proposes Changing the Overpayment Rule’s “Identified” Definition |
McDermott Will & Schulte LLP |
| Dec 24 2022 |
The Greatest Gift of All…Tri-Agencies Issue Welcome Relief on Prescription Drug Reporting |
Proskauer Rose LLP |
| Dec 23 2022 |
OECD Accepting Comment on Draft Study Report on Applicability of the key event based TG 442D for in vitro skin sensitisation testing of nano-materials |
Bergeson & Campbell, P.C. |
| Dec 22 2022 |
Omnibus Bill for Fiscal Year 2023 (H.R. 2617) – Cosmetics Summary |
Keller and Heckman LLP |
| Dec 22 2022 |
Consumer Reports Evaluates Heavy Metals in Chocolate |
Keller and Heckman LLP |
| Dec 22 2022 |
Heinz PFAS Consumer Fraud Lawsuit Continues 2022 Trend |
CMBG3 Law |
| Dec 21 2022 |
PTO Expands the Scope of the Immunotherapy Pilot Program |
Schwegman, Lundberg & Woessner, P.A. |
| Dec 21 2022 |
ANSES Applies Methodology to Assess Risks of Nanomaterials in Food to Titanium Dioxide |
Bergeson & Campbell, P.C. |
| Dec 21 2022 |
FTC Revises Longstanding “Dietary Supplement Guide” to Cover all Health Products |
Hunton Andrews Kurth |
| Dec 21 2022 |
FDA Issues Final Guidance on GRAS Panel Best Practices |
Keller and Heckman LLP |
| Dec 20 2022 |
Comment Period for “Healthy” Regulations Extended; But Consumer Class Actions Targeting “Health Halos” May Continue |
Sheppard, Mullin, Richter & Hampton LLP |
| Dec 20 2022 |
OSTP Publishes RFIs on Coordinated Framework for the Regulation of Biotechnology and National Biotechnology and Biomanufacturing Initiative |
Bergeson & Campbell, P.C. |
| Dec 20 2022 |
Mississippi Department of Health Releases Proposed Modifications to Medical Cannabis Regulations |
Bradley Arant Boult Cummings LLP |
| Dec 20 2022 |
California Legislative Update Part II: Upcoming Changes for Health Facilities |
Mintz |
| Dec 20 2022 |
Office of Science and Technology Policy Requests Public Input on Biotechnology Regulation |
Keller and Heckman LLP |
| Dec 19 2022 |
340B Hospital Reimbursement Update – Underpayments and the Need to Act Now |
Polsinelli PC |
| Dec 19 2022 |
Proposed Changes to the Canadian Feed Ingredients Table |
Keller and Heckman LLP |
| Dec 16 2022 |
FTC Starts Long-Awaited Green Guides Review |
Keller and Heckman LLP |
| Dec 16 2022 |
EUON Announces Results of Desk Study on (Bio)degradation, Persistence, and SbD of Nanomaterials |
Bergeson & Campbell, P.C. |
| Dec 15 2022 |
Psychedelic Drugs – Easing the Regulatory Hurdles for Development |
Foley & Lardner LLP |
| Dec 15 2022 |
Economically Motivated Adulteration in Honey |
Keller and Heckman LLP |
| Dec 15 2022 |
China Announces New Management Measures for Food-Related Products |
Keller and Heckman LLP |
| Dec 14 2022 |
FDA Published Food Safety Culture Literature Review |
Keller and Heckman LLP |
| Dec 13 2022 |
California’s Newly Adopted “Safe Harbor” Warning Label for Acrylamide In Foods Turns Up the Heat In Ongoing First Amendment Challenge to Proposition 65 |
Sheppard, Mullin, Richter & Hampton LLP |
| Dec 13 2022 |
FDA Letter States that β-Nicotinamide Mononucleotide is Not Lawful Dietary Supplement |
Keller and Heckman LLP |
| Dec 13 2022 |
Warning Sign? A New Round of FDA Warning Letters Over CBD Consumer Confusion May Signal a Shift in Government Enforcement |
Bradley Arant Boult Cummings LLP |
| Dec 12 2022 |
American Hospital Association Urges DEA to Issue Special Registration for Telemedicine Controlled Substances |
Foley & Lardner LLP |
